Aligos Therapeutics, Inc. (ALGS) is a clinical-stage biopharmaceutical company based in South San Francisco, focused on therapies for liver and viral diseases, primarily chronic hepatitis B (HBV) and metabolic dysfunction-associated steatohepatitis (MASH). Six current analyst price targets were reviewed: H.C. Wainwright at $50 (reiterated July 7, 2026), Lake Street at $45 (initiated May 28, 2026 by analyst Daniel Brims), Jefferies at $48 (initiated March 19, 2026), Piper Sandler at $175 (maintained August 7, 2026), and Cantor Fitzgerald and UBS each at $20. The calculated mean is approximately $59.67, rounded to $60 as the central target. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The spread between the lowest ($20) and highest ($175) targets is extraordinarily wide for a small-cap biotech, signaling genuine disagreement about how much of the pipeline's potential is already reflected in valuation. Nearly all ratings are Buy, but the targets were set before a sharp mid-November 2026 decline, and several may not have been revised to reflect the lower share price. A downgrade from Weiss Ratings in September 2026 also introduced a more cautious, sell-side view without a published target.
ALGS traded near $2.10 as of November 13, 2026, with a market capitalization of roughly $13 million and a 52-week range of $1.92 to $13.69. Reaching $60 would require a rise of about 2,757% — an extremely large move by any standard, far larger than a typical analyst-target gap. The stock declined sharply in the week ending November 13, falling from roughly $4.50 to around $2.10.
For the third quarter of 2026, reported November 6, Aligos narrowed its net loss to $21.9 million, or $2.09 per share, beating consensus estimates, though revenue of roughly $2.9 million came in below expectations. Cash, equivalents, and investments totaled about $31.1 million at September 30, 2026 — a figure that actually exceeds the company's market capitalization, a condition that often signals investor skepticism about future value creation.
The 52-week low of $1.92, reached around November 12, 2026, stands as the nearest support level, with the stock trading just above it. The rapid decline from the $4.50 area in early November left little established technical structure in between, while the upper part of the 52-week range near $13.69 represents a distant, longer-term reference point. For a low-priced stock in a downtrend, the $2.00 round-number level is a key psychological support that investors are watching closely. From what I see, this setup warrants careful monitoring of volume and any reversal signals.
Analyst price targets typically reflect a roughly 12-month research horizon, though for ALGS several targets appear tied to catalysts that lie further out. The pivotal item is the B-SUPREME topline data readout, expected late in the third quarter of 2027. Investors should also track quarterly cash and financing updates, any new equity issuance, fourth-quarter results, progress on the ALG-055009 and ALG-170675 programs, and analyst revisions to price targets following the recent share-price decline. I’m watching this closely for any updates on financing needs.
In my analysis of names like this, Tickeron's AI Daily Buy/Sell Signals provide a useful layer by applying artificial intelligence to monitor market conditions and technical behavior across thousands of stocks. For a volatile, low-priced name like ALGS, these signals can offer an additional data-driven perspective on momentum shifts that complements traditional research.
The $60 central target for Aligos Therapeutics (ALGS) is the average of six analyst price targets ranging from $20 to $175. Because the shares trade near $2.10, the implied upside of roughly 2,757% is extraordinarily large and reflects targets that were largely set before the November decline. Positive clinical progress, narrowing losses, and a partnered pipeline offer a foundation for a recovery, but a short cash runway, reliance on binary readouts, and an exceptionally wide target range underscore how much uncertainty remains. Whether ALGS approaches $60 depends on financing execution and future clinical data — outcomes that remain far from certain.
I regularly turn to Tickeron's AI Daily Buy/Sell Signals when reviewing clinical-stage names like this one. The tool helps surface potential momentum changes based on AI analysis of technical and market data, giving me one more lens alongside my own review of fundamentals and analyst views. It has become a practical part of how I cross-check ideas before digging deeper.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
ALGS saw its Momentum Indicator move below the 0 level on November 05, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 89 similar instances where the indicator turned negative. In 83 of the 89 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
The Moving Average Convergence Divergence Histogram (MACD) for ALGS turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 45 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALGS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ALGS entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALGS advanced for three days, in 186 of 237 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
ALGS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Seasonality Score of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.797) is normal, around the industry mean (3.498). P/E Ratio (-0.528) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.658) among similar stocks. P/S Ratio (1.680) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. ALGS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALGS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry Biotechnology